Filgotinib is an oral medication that belongs to a group called targeted synthetic DMARDs. It works by blocking specific enzymes that cause inflammation in the joints. In this study it is one of the drugs that may be reduced in dose for patients who choose to taper their treatment.
Baricitinib is another oral targeted synthetic DMARD. It reduces inflammation by inhibiting enzymes involved in the immune response. The trial examines whether patients can safely lower the amount of baricitinib they take while keeping their arthritis under control.
Infliximab is a biologic drug given by infusion. It is an antibody that blocks a protein called tumor necrosis factor (TNF), which drives joint inflammation. Participants may have their infliximab dose decreased as part of the tapering strategy.
Certolizumab pegol is an injectable biologic that also targets TNF to reduce inflammation. In the study it is used as a treatment that could be tapered down for patients who prefer to reduce their medication load.
Hydroxychloroquine is an oral conventional DMARD that has anti‑inflammatory effects and is often used in rheumatoid arthritis. The trial looks at whether the dose of hydroxychloroquine can be lowered without worsening disease activity.
Upadacitinib is an oral targeted synthetic DMARD that blocks a pathway called JAK, helping to control joint inflammation. The study tests if patients can safely taper the amount of upadacitinib they receive.
Adalimumab is an injectable biologic that neutralizes TNF, reducing swelling and pain in the joints. Researchers are evaluating whether the dose of adalimumab can be reduced while maintaining disease control.
Sulfasalazine is an oral conventional DMARD that works by decreasing inflammation in the body. In this trial it may be part of the medication regimen that participants try to taper.
Sarilumab is an injectable biologic that blocks the interleukin‑6 (IL‑6) receptor, a key driver of joint inflammation. The study includes sarilumab as a drug that could be tapered for patients who choose that option.
Tocilizumab is an injectable or infusion biologic that also blocks the IL‑6 receptor, helping to lessen joint damage. Participants may have their tocilizumab dose reduced as part of the tapering approach.
Methotrexate is a cornerstone conventional DMARD taken either by injection or orally. It works by slowing down the immune system’s attack on joint tissue. The trial investigates whether patients can lower their methotrexate dose while staying in low disease activity.
Golimumab is an injectable biologic that targets TNF to reduce inflammation. In the study it is considered for dose reduction in the tapering group.
Abatacept is a biologic given by infusion that interferes with a specific step in T‑cell activation, which helps control rheumatoid arthritis. The trial examines if the amount of abatacept can be safely tapered.
Prednisolone is an oral steroid that quickly reduces inflammation and pain. Although not a DMARD, it is used in the study to manage symptoms and may be adjusted as part of the overall treatment plan.
Tofacitinib is an oral targeted synthetic DMARD that inhibits JAK enzymes, lowering inflammatory activity in the joints. The study assesses whether patients can decrease their tofacitinib dose while keeping disease activity stable.
Leflunomide is an oral conventional DMARD that reduces the production of immune cells that cause joint damage. In this trial it may be one of the medications that participants try to taper.
Etanercept is an injectable biologic that binds to TNF, preventing it from causing inflammation. The research looks at whether the dose of etanercept can be reduced without worsening rheumatoid arthritis symptoms.
Denmark 
